1. Generics Bulletin
  2. >>ESG

Medicines For Europe’s Sieger: ‘We Have To Create An Ecosystem Where We Can Compete’

Generics Bulletin Hosts Exclusive Interview With Association VP And Polpharma CEO

 
• By Dean Rudge

Markus Sieger, vice-president of off-patent industry association Medicines for Europe and CEO of Polpharma, spoke to Generics Bulletin about critical issues affecting supply in Europe, including pricing, supply chains, and his enthusiasm for ESG.

“We have these issues which we face in Europe. And the solution, I think, is not just to get money to build a factory, you know, or grants to develop products,” vice president of off-patent industry association Medicines for Europe and CEO of Polpharma, Markus Sieger, tells Generics Bulletin during an exclusive interview.

“I think we have to create an ecosystem where we can compete in supplying those products at a fair price. I think it takes more than just money to fix...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ESG

‘Creating An Environment Where Women Can Thrive’ – Accord’s Carter Discusses The BGMA Women’s Networking Group

 
• By Dave Wallace

Marking International Women’s Day, Generics Bulletin speaks to Accord’s UK country manager Clara Carter about her role as chair of the BGMA’s new Women’s Networking Group.

‘A True Seat At The Table’ – Irish Industry Leader Sets Out Aspirations For New Pricing Deal

 
• By Dave Wallace

With a fresh pricing deal on the horizon, Medicines for Ireland chair and Teva country head Paul Neill talks to Generics Bulletin about the need for the Irish off-patent industry to have “a true seat at the table” and secure an agreement with the country’s government that better reflects the specificities of the generics and biosimilars market.

Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector

 
• By Urtė Fultinavičiūtė

With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.

Biosimilars Forum Sees Lessons Being Learned From US Humira Experience

 
• By Dave Wallace

In an interview with Generics Bulletin, Julie Reed, executive director of the US Biosimilars Forum, says that the low uptake for Humira rivals in the US has “raised everyone’s attention to what is going on and what is wrong with the system.”

More from Generics Bulletin

Fresenius Adds To Denosumab Competitors In Europe

 
• By Dave Wallace

At a busy meeting of the CHMP, the EMA issued positive opinions for Fresenius Kabi’s denosumab rivals to Prolia and Xgeva, another denosumab biosimilar from Sandoz, a Tecfidera hybrid from Neuraxpharm and a Descovy generic from Viatris. Meanwhile, Ascend has withdrawn a teriparatide filing.

Alvotech And Advanz Add Three More In €160m EU Partnership Expansion

 
• By Dean Rudge

Fresh from filing a proposed biosimilar to Xolair (omalizumab) in the UK, Alvotech and Advanz have shaken hands on a further deal to expand their partnership.

After Dasatinib Apotex Debuts US Tasigna Competition

 
• By Dean Rudge

Canada’s Apotex is continuing to spearhead generic competition in the tyrosine kinase inhibitor (TKI) space for chronic myelogenous leukemia, with the launch of the first generic version of Novartis’ Tasigna (nilotinib) blockbuster.